Tag: Metastatic colorectal cancer
Lupin, Enzene Biosciences to launch cancer drug Cetuximab biosimilar in India
Lupin, an Indian pharmaceutical company, has announced a strategic collaboration with Enzene Biosciences, a subsidiary of Alkem Laboratories, to introduce Cetuximab in India. Cetuximab is ... Read More
Takeda signs licensing deal for Hutchmed’s fruquintinib outside of China
Takeda Pharmaceutical will acquire an exclusive worldwide license, excluding China, of fruquintinib from Hutchmed (China) and its subsidiary Hutchmed to strengthen its oncology portfolio. Under ... Read More
Seagen gets FDA accelerated approval for tucatinib, trastuzumab combo for colorectal cancer
American biotechnology company Seagen (formerly Seattle Genetics) has received accelerated approval from the US Food and Drug Administration (FDA) for the company’s oral drug Tukysa ... Read More
Array BioPharma Braftovi triple combo for metastatic colorectal cancer secures FDA breakthrough therapy designation
Array BioPharma secured breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for encorafenib (BRAFTOVI), in combination with binimetinib (MEKTOVI) and cetuximab for ... Read More
Vyriad, Merck to launch phase 1 study of immuno oncology drugs Voyager-V1 and avelumab
Vyriad, a US biotech company, has entered into a collaboration with Germany-based Merck to launch a phase 1 trial of their immuno oncology drugs combination ... Read More